Technical Analysis for ELOX - Eloxx Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.00 | 11.11% | 0.10 |
Earnings due: Mar 29
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bullish Engulfing | Bullish | 11.11% | |
Narrow Range Bar | Range Contraction | 11.11% | |
Lower Bollinger Band Walk | Weakness | 11.11% | |
New 52 Week Low | Weakness | 11.11% | |
Wide Bands | Range Expansion | 11.11% | |
Oversold Stochastic | Weakness | 11.11% | |
New 52 Week Closing Low | Bearish | 21.95% | |
New Downtrend | Bearish | 21.95% | |
NR7 | Range Contraction | 21.95% | |
Narrow Range Bar | Range Contraction | 21.95% |
Alert | Time |
---|---|
Rose Above Previous Day's High | 40 minutes ago |
Up 5% | 40 minutes ago |
Up 3% | 40 minutes ago |
Up 2% | 40 minutes ago |
Up 1% | 40 minutes ago |
Get this analysis on your stocks daily!
- Earnings date: 03/29/2024
Eloxx Pharmaceuticals, Inc. Description
Eloxx Pharmaceuticals, Inc. (ELOX) is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Clinical Development Rare Diseases Molecular Biology Genetics Gene Expression Genetic Diseases Cystic Fibrosis Molecular Genetics Messenger RNA Rehovot Protein Biosynthesis Rare And Ultra Rare Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 10.9 |
52 Week Low | 0.7705 |
Average Volume | 46,753 |
200-Day Moving Average | 5.09 |
50-Day Moving Average | 4.53 |
20-Day Moving Average | 3.66 |
10-Day Moving Average | 2.60 |
Average True Range | 0.50 |
RSI (14) | 17.36 |
ADX | 28.12 |
+DI | 9.79 |
-DI | 46.93 |
Chandelier Exit (Long, 3 ATRs) | 3.99 |
Chandelier Exit (Short, 3 ATRs) | 2.27 |
Upper Bollinger Bands | 6.72 |
Lower Bollinger Band | 0.59 |
Percent B (%b) | 0.05 |
BandWidth | 167.60 |
MACD Line | -1.05 |
MACD Signal Line | -0.67 |
MACD Histogram | -0.3771 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.99 | ||||
Resistance 3 (R3) | 0.96 | 0.89 | 0.97 | ||
Resistance 2 (R2) | 0.89 | 0.87 | 0.91 | 0.97 | |
Resistance 1 (R1) | 0.90 | 0.86 | 0.89 | 0.93 | 0.96 |
Pivot Point | 0.83 | 0.83 | 0.83 | 0.85 | 0.83 |
Support 1 (S1) | 0.84 | 0.81 | 0.84 | 0.87 | 0.84 |
Support 2 (S2) | 0.77 | 0.80 | 0.79 | 0.83 | |
Support 3 (S3) | 0.78 | 0.77 | 0.83 | ||
Support 4 (S4) | 0.81 |